|
FDA Tackles Gender Differences in Revised ICH Guidance on QT Interval Prolongation
The FDA has revised and clarified a final ICH question-and-answer guidance on the evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives